Scienture Holdings, Inc. SCNX
information included in this Annual Report should be read in conjunction with the consolidated financial statements and related notes
in "Item 8. Financial Statements and Supplemental Data" of this Annual Report.
logo and some of our trademarks and tradenames are used in this Annual Report. This Annual Report may also include trademarks, tradenames
and service marks that are the property of others. Solely for convenience, trademarks, tradenames and service marks referred to in this
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $431.6K | $136.6K | $1.4M | $10.3M | $9.9M | $17.1M | $7.4M | $3.8M | $2.9M | $2.5M |
| Cost of revenue | $100.1K | $130.6K | $1.3M | $4.7M | $5.1M | $11.4M | $2.6M | $449.0K | — | $16.4K |
| Gross profit | $331.5K | $6.0K | $49.0K | $5.5M | $4.7M | $5.7M | $4.9M | $3.4M | $2.9M | $2.5M |
| R&D | $2.0M | $2.2M | — | — | — | — | — | — | — | — |
| SG&A | $7.9M | $6.7M | $1.3M | $1.7M | $1.9M | $7.5M | $4.4M | $3.5M | $2.5M | $3.5M |
| Total operating expenses | $42.9M | $14.7M | $4.4M | $8.4M | $10.0M | $8.2M | $4.7M | $3.5M | — | — |
| Operating income | -$42.6M | -$14.7M | -$4.4M | -$2.9M | -$5.3M | -$2.5M | $125.2K | -$87.6K | $395.1K | -$1.0M |
| Interest expense | $4.1M | $1.3M | $1.1M | $336.2K | $23.6K | $29.4K | $53.2K | $57.5K | $157.1K | $151.5K |
| Pre-tax income | -$43.5M | -$18.8M | -$8.5M | — | — | — | — | — | — | — |
| Income tax | $2.0M | $534.4K | — | — | — | — | — | — | — | — |
| Net income | -$41.5M | $9.1M | -$17.8M | -$3.5M | -$5.3M | -$2.5M | -$284.4K | $9.0K | $289.0K | -$2.8M |
| EPS, basic | -2.70 | 2.69 | -23.35 | -6.15 | -0.65 | — | -0.05 | 0.00 | 0.01 | -0.09 |
| EPS, diluted | -2.70 | 2.48 | -23.35 | -6.13 | -0.65 | -0.33 | -0.05 | 0.00 | 0.01 | -0.09 |
| Shares, diluted (wtd. avg.) | $15.3M | $3.7M | $2.4M | $566.6K | $8.1M | — | $5.9M | $5.8M | $34.1M | $31.5M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $6.7M | — | $151.9K | $1.1M | $3.1M | $5.9M | $2.9M | $869.6K | $183.9K | $14.7K |
| Receivables | $731.3K | $11.1K | $821.8K | $629.9K | $979.0K | $805.0K | $792.0K | $433.6K | $319.5K | $299.1K |
| Inventory | $213.4K | — | $968 | $65.5K | $56.3K | $1.3M | $56.8K | $80.0K | — | — |
| Total current assets | $7.9M | $6.3M | $2.8M | $2.1M | $4.4M | $9.2M | $3.8M | $1.5M | $607.5K | $337.1K |
| Property, plant and equipment | $15.5K | $17.5K | $7.5K | $65.2K | $98.8K | $162.4K | $175.0K | $15.0K | — | — |
| Goodwill | — | $21.4M | — | $0 | $0 | — | $726.0K | $726.0K | — | — |
| Other intangibles | $71.0M | $76.4M | $9.0M | — | $792.0K | — | — | — | — | — |
| Total assets | $84.2M | $104.9M | $12.5M | $3.7M | $5.8M | $9.8M | $5.6M | $2.2M | $617.5K | $337.1K |
| Accounts payable | $1.4M | $2.9M | $1.5M | $528.0K | $477.0K | $256.8K | $334.6K | $400.5K | $106.1K | $236.8K |
| Total current liabilities | $2.7M | $7.9M | $11.6M | $2.1M | $926.0K | $842.2K | $520.8K | $860.4K | $525.4K | $1.5M |
| Long-term debt | — | $2.9M | — | — | — | — | $225.0K | $522.1K | $666.5K | — |
| Total liabilities | $14.1M | $25.8M | $12.0M | $3.4M | $2.0M | $1.1M | $1.4M | $1.4M | $929.4K | $1.5M |
| Retained earnings | -$80.6M | -$39.0M | -$33.2M | -$19.7M | -$16.2M | -$10.9M | -$8.4M | -$8.1M | -$8.1M | -$8.4M |
| Total equity | $70.1M | $79.1M | $542.4K | $342.9K | $3.8M | $8.7M | $4.1M | $844.7K | -$311.9K | -$1.1M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$13.4M | -$14.3M | -$2.2M | -$199.0K | -$2.6M | -$2.2M | $141.8K | $273.4K | $171.7K | -$503.5K |
| Depreciation and amortisation | $2.0K | $2.0K | $19.4K | $13.5K | $7.4K | $5.5K | $5.0K | — | $13.0K | $0 |
| Stock-based compensation | $2.1M | $25.6K | $29.7K | $79.2K | $64.2K | $448.4K | $176.4K | — | — | — |
| Capital expenditure | — | $12.0K | — | — | $22.6K | $37.5K | — | — | — | — |
| Investing cash flow | — | $27.6M | -$275.7K | $749 | -$22.6K | -$37.5K | -$332.3K | -$265.3K | $0 | -$78.0K |
| Financing cash flow | $19.7M | -$13.0M | $1.4M | $239.8K | -$208.2K | $5.3M | $2.2M | $677.5K | -$2.4K | $621.4K |
| Dividends paid | — | $2.2M | $12.7M | — | — | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-020707.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |